9885.HK
Strong BuyUnloved QualityAI neutralYSB Inc. · Healthcare · China · $297M
HKD 3.52 +0.4% · close 6 Oct · scored 7 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
YSB Inc. runs a Chinese B2B pharmaceutical marketplace that supplies drugs to pharmacies and clinics. The shares look cheap and the company has been buying back stock actively (0.47% of shares over 26 filing days in 90 days). However, insiders sold 0.84% of shares over the same period, more than the company bought back. Drug distribution in China runs on thin margins and faces price pressure from volume-based procurement. Momentum is weak. The mix of insider selling and a thin-margin model does not support a bull case.
ABOUT YSB INC.
Read
YSB Inc. operates a leading B2B e-commerce platform for pharmaceuticals and healthcare products in China, connecting drug manufacturers and distributors with pharmacies and clinics. As a dominant online platform in China's fragmented pharmaceutical distribution market, it leverages network effects, vast product selection, and efficient supply chain management. The company benefits from the ongoing digital transformation in the healthcare sector.
FINANCIAL SUMMARY (HKD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | 11.8B | 16.7B | 19.9B | 21.0B | 24.6B | 20.1% | 25.1B |
| EPS (HKD) | -0.93 | -2.78 | -9.68 | 0.06 | 0.26 | 348.0% | 0.32 |
| Shares | 632.4M | 632.4M | 640.2M | 675.2M | 679.4M | +7.4% | 687.3M |
| Debt | 213.1M | 211.7M | 245.8M | 273.8M | 383.9M | 15.9% | 346.6M |
| Equity | -3.4B | -5.1B | 2.3B | 2.7B | 2.9B | 12.8% | — |
| Op CF | -571.1M | 115.1M | 529.0M | 769.0M | 747.7M | 86.6% | 754.9M |
| Inv CF | -413.6M | 48.2M | -929.7M | -297.3M | -1.1B | — | — |
| Fin CF | 1.3B | 307.1M | 299.4M | -128.7M | -83.2M | — | — |
Swung more than 77% of stocks we rank over the past year (62% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 9885.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 9885.HK | YSB Inc.(you) | $297M | 89 | Strong Buy |
| 1345.HK | Shanghai Pioneer Holding Ltd | $331M | 97 | Strong Buy |
| 002727.SZ | Yixintang Pharmaceutical Group Co., Ltd. | $925M | 87 | Strong Buy |
| 603883.SS | LBX Pharmacy Chain Joint Stock Company | $1.5B | 89 | Strong Buy |
| 301408.SZ | Anhui Huaren Health Pharmaceutical Co., Ltd. | $885M | 61 | Hold |
| 603233.SS | DaShenLin Pharmaceutical Group Co., Ltd. | $3.0B | 96 | Strong Buy |
| 002788.SZ | Luyan Pharma Co.,Ltd. | $630M | 47 | Hold |
| 603939.SS | Yifeng Pharmacy Chain Co., Ltd. | $4.0B | 94 | Strong Buy |
| 6086.HK | Fangzhou Inc. | $136M | 46 | Hold |
| 301017.SZ | ShuYu Civilian Pharmacy Corp., Ltd. | $800M | 50 | Hold |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 53.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.